Home » Stocks » SRRA

Sierra Oncology, Inc. (SRRA)

Stock Price: $17.93 USD -0.47 (-2.55%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $18.06 +0.13 (0.73%) Apr 16, 4:00 PM
Market Cap 210.01M
Revenue (ttm) 300,000
Net Income (ttm) -80.90M
Shares Out 11.63M
EPS (ttm) -7.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $17.93
Previous Close $18.40
Change ($) -0.47
Change (%) -2.55%
Day's Open 18.33
Day's Range 17.70 - 18.44
Day's Volume 17,592
52-Week Range 10.02 - 20.43


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

For all practical purposes, Sierra Oncology today is a single product company, solely focused on its most advanced product, momelotinib, which is targeted at Myelofibrosis. There will likely be easier t...

2 months ago - Seeking Alpha

- Ms. Thomson brings extensive strategic, transactional and intellectual property experience as Sierra prepares for potential transition into a commercial company -

8 months ago - GlobeNewsWire

Sierra Oncology, Inc (SRRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

10 months ago - Zacks Investment Research

Sierra Oncology, Inc. (SRRA) Nick Glover on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Sierra Oncology (SRRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.

1 year ago - Zacks Investment Research

Sierra Oncology has been struggling lately, but the selling pressure may be coming to an end soon.

1 year ago - Zacks Investment Research

About SRRA

Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has two completed Phase 3 trials for the treatment of myelofibrosis. The company also develops SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly know... [Read more...]

IPO Date
Jul 16, 2015
Stephen Dilly
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for SRRA stock is "Strong Buy." The 12-month stock price forecast is 27.75, which is an increase of 54.77% from the latest price.

Price Target
(54.77% upside)
Analyst Consensus: Strong Buy